ES2216630T3 - Metodos de tratar la hipertension dependiente de la sal. - Google Patents

Metodos de tratar la hipertension dependiente de la sal.

Info

Publication number
ES2216630T3
ES2216630T3 ES99968631T ES99968631T ES2216630T3 ES 2216630 T3 ES2216630 T3 ES 2216630T3 ES 99968631 T ES99968631 T ES 99968631T ES 99968631 T ES99968631 T ES 99968631T ES 2216630 T3 ES2216630 T3 ES 2216630T3
Authority
ES
Spain
Prior art keywords
methods
salt
dependent hypertension
treating
treating dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99968631T
Other languages
English (en)
Inventor
George F Schreiner
Richard J Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Scios LLC
Original Assignee
University of Washington
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Scios LLC filed Critical University of Washington
Application granted granted Critical
Publication of ES2216630T3 publication Critical patent/ES2216630T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso del factor de crecimiento vascular endotelial (VEGF) o un agonista del mismo en una cantidad eficaz para reducir la presión sanguínea a un intervalo normal, en la fabricación de un medicamento para el tratamiento de la hipertensión dependiente de la sal.
ES99968631T 1998-09-09 1999-09-09 Metodos de tratar la hipertension dependiente de la sal. Expired - Lifetime ES2216630T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27

Publications (1)

Publication Number Publication Date
ES2216630T3 true ES2216630T3 (es) 2004-10-16

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99946776T Expired - Lifetime ES2211165T3 (es) 1998-09-09 1999-09-09 Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.
ES99968631T Expired - Lifetime ES2216630T3 (es) 1998-09-09 1999-09-09 Metodos de tratar la hipertension dependiente de la sal.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99946776T Expired - Lifetime ES2211165T3 (es) 1998-09-09 1999-09-09 Uso de un factor angiogenico para el tratamiento de angiopatias microvasculares.

Country Status (13)

Country Link
US (3) US6352975B1 (es)
EP (2) EP1112083B1 (es)
JP (2) JP2002532382A (es)
AT (2) ATE260675T1 (es)
AU (2) AU5910599A (es)
BR (2) BR9913533A (es)
CA (2) CA2340320C (es)
DE (2) DE69915310T2 (es)
DK (2) DK1112083T3 (es)
ES (2) ES2211165T3 (es)
IL (2) IL141686A0 (es)
PT (2) PT1112083E (es)
WO (2) WO2000013703A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2340320C (en) * 1998-09-09 2006-11-14 Scios Inc. Use of an angiogenic factor for the treatment of microascular angiopathies
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
EP1225910A2 (en) * 1999-11-02 2002-07-31 Genentech, Inc. MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
JP4689956B2 (ja) 2001-08-01 2011-06-01 ユニバーシティ オブ ブリストル 増殖因子イソ型
CA2459647A1 (en) * 2001-08-20 2003-02-27 University Of Virginia Patent Foundation Use of s-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
BRPI0610499A2 (pt) * 2005-04-12 2010-06-22 Intradigm Corp moléculas de ácido nucléico , composições e usos das referidas moléculas
JP5158779B2 (ja) * 2005-08-31 2013-03-06 国立大学法人 香川大学 Ｄ−アロースを有効成分とする血圧上昇抑制剤
MX2011005912A (es) * 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
GB0921525D0 (en) 2009-12-08 2010-01-27 Isis Innovation Product and method
JP2020512338A (ja) 2017-03-30 2020-04-23 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 腎臓疾患の治療方法
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
IL93846A0 (en) 1989-03-24 1990-12-23 Univ California Endothelial cell growth factor,methods of isolation and expression
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
EP0941116B1 (en) 1996-11-01 2005-01-19 Ark Therapeutics Limited Use of vegf for the manufacture of a medicament for the treatment or prevention of intimal hyperplasia and delivery device
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
CA2340320C (en) * 1998-09-09 2006-11-14 Scios Inc. Use of an angiogenic factor for the treatment of microascular angiopathies

Also Published As

Publication number Publication date
EP1112083A2 (en) 2001-07-04
WO2000013703A2 (en) 2000-03-16
PT1112083E (pt) 2004-03-31
IL141686A0 (en) 2002-03-10
US6352975B1 (en) 2002-03-05
DE69912815T2 (de) 2004-10-21
PT1109571E (pt) 2004-05-31
ATE253934T1 (de) 2003-11-15
EP1109571B1 (en) 2004-03-03
WO2000013703A3 (en) 2000-07-06
DK1109571T3 (da) 2004-06-21
CA2340320C (en) 2006-11-14
DE69915310T2 (de) 2005-03-10
DE69915310D1 (de) 2004-04-08
WO2000013702A9 (en) 2000-10-19
JP2002524421A (ja) 2002-08-06
EP1109571A2 (en) 2001-06-27
ATE260675T1 (de) 2004-03-15
BR9913533A (pt) 2001-06-05
BR9913564A (pt) 2001-05-22
WO2000013702A3 (en) 2000-09-08
US20040224885A1 (en) 2004-11-11
CA2340320A1 (en) 2000-03-16
AU6028599A (en) 2000-03-27
AU5910599A (en) 2000-03-27
JP2002532382A (ja) 2002-10-02
US20020193288A1 (en) 2002-12-19
CA2340728A1 (en) 2000-03-16
WO2000013703A9 (en) 2000-06-02
EP1112083B1 (en) 2003-11-12
DE69912815D1 (de) 2003-12-18
CA2340728C (en) 2007-11-27
WO2000013702A2 (en) 2000-03-16
DK1112083T3 (da) 2004-03-08
IL141687A0 (en) 2002-03-10
ES2211165T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
PL328858A1 (en) Immunogenous peptides
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
ATE295355T1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
TR200200205T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
BG104247A (en) Resorcinol derivatives
DE69928690D1 (de) Zusammensetzung und Verfahren zur Bindung von Hautirritierenden Mitteln.
TR200200068T2 (tr) Nematisital triflüorobütenler
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
MX9702170A (es) Uso de inhibidores de la aromatasa para la produccion de un agente farmaceutico para el tratamiento de una deficiencia de androgeno relativa en los hombres.
BR9912327A (pt) Inibidores da uroquinase
ATE215379T1 (de) Antifungaleverfahren und mitteln
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
ATE263555T1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
EP1447089A3 (en) Methods of treating hypertension and compositions for use therein
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE69924385D1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
BR9710992A (pt) Derivados anticovulsivos úteis no tratamento de psorìase
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
ES2122912A1 (es) Inhibidores de metalocarboxipeptidasas y moleculas derivadas como agentes antitumorales.